Mount Sinai Researcher Receives Prestigious International Award
Mone Zaidi, MD, PhD, is recognized for contributions to bone and mineral research
Mone Zaidi, MD, PhD, Director of the Center for Translational Medicine and Pharmacology and Professor of Medicine, and Pharmacological Sciences, at the Icahn School of Medicine at Mount Sinai, has received the 2022 International Research Prize from the Austrian Bone and Mineral Society, the largest medical society in Austria. The International Research Prize is the most coveted prize in bone and mineral research and is given once every three years.
Since its inception in 1988, the International Research Prize has been presented to individuals whose recent work in the fields of molecular, cellular, or material science, or the pathophysiological or clinical aspects of bone and mineral metabolism, has resulted in a novel finding or concept.
An international jury independently selected Dr. Zaidi as the prize winner, and he was awarded EUR 7,500 ($8,000 USD) at the Osteoporoseforum, the 30th annual Meeting of the Austrian Bone and Mineral Society, which was held in St. Wolfgang, Austria, on June 23-25. The following pieces of Dr. Zaidi’s work were featured during this conference.
- Oxytocin regulates body composition. Proceedings of the National Academy of Sciences 116: 26808-26815.
- First-in-class humanized FSH blocking antibody targets bone and fat. Proceedings of the National Academy of Sciences 117: 28971-28979.
- FSH blockade improves cognition in mice with Alzheimer’s disease. Nature 603: 470-476.
“It is a truly humbling experience to be awarded this prize and to join this small group of luminaries in my field—something that I could not have achieved without the exceptionally talented faculty and trainees and distinguished collaborators that I have had the honor of working with over these years,” said Dr. Zaidi.
Dr. Zaidi has made groundbreaking discoveries on mechanisms of skeletal homeostasis in health and disease. These studies, spanning more than 30 years, included the first description of calcium sensing in the osteoclast and the discovery that locally released nitric oxide acts to suppress bone cells. In 2003, Dr. Zaidi’s group published the first evidence for a pituitary-bone axis, a breakthrough in physiology in which pituitary hormones could affect the skeleton directly. In recent groundbreaking papers in Nature, he found that inhibiting the follicle-stimulating hormone (FSH) not only increased bone mass, but also reduced body fat and neurodegeneration—in essence laying a firm foundation for a single anti-FSH agent to treat osteoporosis, obesity, and Alzheimer’s disease.
The corpus of work relating FSH to body fat was selected by Nature Medicine as one of the eight “Notable Advances” in biomedicine for 2017. Constituting a total of more than 450 publications in journals, Dr. Zaidi’s research has been funded continuously by the National Institutes of Health (NIH). He has also chaired multiple Study Sections for the NIH and the Department of Veterans Affairs. He served as President of the Interurban Clinical Club and was elected to membership of the Association of American Physicians, the Practitioners’ Society (the oldest medical society in the United States) and the Association of Professors of Medicine. Dr. Zaidi is a Master of the American College of Physicians, received the Harrington Scholar-Innovator Award, was elected as Fellow of the American Association of Advancement of Science, and is the recipient of three honorary doctorates.
“Dr. Zaidi is an exceptional researcher who has made pioneering discoveries on the mechanisms of musculoskeletal homeostasis in health and disease throughout his career,” said Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute, and Dean for Academic Affairs of Icahn Mount Sinai, and Chief Scientific Officer of the Mount Sinai Health System. “I congratulate Dr. Zaidi on receiving one of the most prestigious awards in his field and we are thrilled that he is being recognized by the largest medical society in Austria.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.